SCHEMBL5653663

SCHEMBL5653663

COc1ccc2[nH]c(-c3ccc(C(=O)NCCCN4CCOCC4)cc3)nc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 4/20 0.57
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
HPGD P15428 2/20 0.57
GAA P10253 2/20 0.57
CYP1A2 P05177 1/20 0.57
GLA P06280 1/20 0.57
CYP3A4 P08684 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TDP1 Q9NUW8 1/20 0.56
MAPT P10636 1/20 0.56
CYP2C9 P11712 2/20 0.55
CYP2D6 P10635 1/20 0.55
FGFR1 P11362 1/20 0.52
FGFR2 P21802 1/20 0.52
FGFR3 P22607 1/20 0.52
KDR P35968 1/20 0.52
POLB P06746 1/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653653 0.93 FGFR1 (0.58) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL5654271 0.88 KMT2A (0.56) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL5651436 0.88 CYP2C9 (0.61) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL5651944 0.88 MEN1 (0.55) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL5652721 0.88 KMT2A (0.55) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL5652001 0.87 KDM4E (0.58) KDM4EALDH1A1HPGDCYP1A2HSD17B10
SCHEMBL5650259 0.86 MEN1 (0.57) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL5653810 0.85 CD274 (0.59) KDM4EALDH1A1CYP2C9CYP2D6POLB
SCHEMBL5650883 0.84 DRD3 (0.60) ALDH1A1MAPTDRD3
SCHEMBL5650316 0.84 HDAC3 (0.54) KDM4EALDH1A1POLBMAPK1DUSP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 KDM4E 1605/4885ALDH1A1 2893/4885KMT2A 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.